5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents

Patent metadata

Field	Value
Publication number	US-11220505-B2
Application number	US-201816496065-A
Country	US
Kind code	B2
Filing date	Mar 15, 2018
Priority date	Mar 21, 2017
Publication date	Jan 11, 2022
Grant date	Jan 11, 2022

Abstract

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

First claim

What is claimed is:

1. A compound having formula (I):

or a pharmaceutically acceptable salt thereof, wherein:
n is 2;
R 1a and R 1b are each independently C 1-6 linear alkyl, or R 1a and R 1b may be taken together with the atom to which they are bound to form a cyclohexyl;
R 2 is a benzene ring that is optionally substituted with 0 to 3 R 3 groups that are not hydrogen;
R 3 is at each occurrence independently selected from the group consisting of hydrogen, OH, NO 2 , halogen, CN, C 1-6 linear alkyl, C 3-7 branched alkyl, C 3-7 cycloalkyl, C 1-6 linear alkoxy, C 3-7 branched alkoxy, C 3-7 cycloalkoxy, C 1-6 linear haloalkyl, C 3-7 branched haloalkyl, C 1-6 linear haloalkoxy, heterocyclyl, —S(C 1-6 linear alkyl), S(C 3-7 branched alkyl), —S(C 3-7 cycloalkyl), —SO 2 (C 1-6 linear alkyl), SO 2 (C 3-7 branched alkyl), —SO 2 (C 3-7 cycloalkyl), COR 5 , CO 2 R 6 , CONR 7a R 7b , SO 2 NR 7a R 7b , NR 8a R 8b , NR 8a COR 9 , NR 8a SO 2 R 10 , and NR 8a SO 2 NR 11a R 11b ;
the terms R 3a , R 3b , R 3c , R 3d , and R 3e may be used to designate individual R 3 groups on a benzene ring;
R 5 is at each occurrence independently selected from the group consisting of H, C 1-6 linear alkyl, C 3-7 branched alkyl, and C 3-7 cycloalkyl;
R 6 is at each occurrence independently selected from the group consisting of C 1-6 linear alkyl, C 3-7 branched alkyl, and C 3-7 cycloalkyl;
R 7a is at each occurrence independently selected from the group consisting of H, C 1-6 linear alkyl, C 3-7 branched alkyl, and C 3-7 cycloalkyl;
R 7b is at each occurrence independently selected from the group consisting of H, C 1-6 linear alkyl, C 3-7 branched alkyl, and C 3-7 cycloalkyl;
R 8a is at each occurrence independently selected from the group consisting of H, C 1-6 linear alkyl, C 3-7 branched alkyl, and C 3-7 cycloalkyl;
R 8b is at each occurrence independently selected from the group consisting of H, C 1-6 linear alkyl, C 3-7 branched alkyl, and C 3-7 cycloalkyl;
R 8a and R 8b may be taken together with the atom to which they are bound to form a ring having from 3 to 7 ring atoms optionally containing an oxygen;
R 9 is at each occurrence independently selected from the group consisting of H, C 1-6 linear alkyl, C 3-7 branched alkyl, and C 3-7 cycloalkyl;
R 10 is at each occurrence independently selected from the group consisting of C 1-6 linear alkyl, C 3-7 branched alkyl, and C 3-7 cycloalkyl;
R 11a is at each occurrence independently selected from the group consisting of hydrogen, C 1-6 linear alkyl, C 3-7 branched alkyl, and C 3-7 cycloalkyl; and
R 11b is at each occurrence independently selected from the group consisting of hydrogen, C 1-6 linear alkyl, C 3-7 branched alkyl, and C 3-7 cycloalkyl.

2. The compound of claim 1 , wherein the compound having formula (I) is a compound having formula (IIa):

or a pharmaceutically acceptable salt thereof wherein:
at least 2 of the group R 3a , R 3b , R 3c , R 3d , and R 3e are hydrogen and 0 to 3 of R 3a , R 3b , R 3c , R 3d , and R 3e are independently selected from the group consisting of OH, NO 2 , halogen, CN, C 1-6 linear alkyl, C 3-7 branched alkyl, C 3-7 cycloalkyl, C 1-6 linear alkoxy, C 3-7 branched alkoxy, C 3-7 cycloalkoxy, C 1-6 linear haloalkyl, C 3-7 branched haloalkyl, C 1-6 linear haloalkoxy, heterocyclyl, —S(C 1-6 linear alkyl), S(C 3-7 branched alkyl), —S(C 3-7 cycloalkyl), —SO 2 (C 1-6 linear alkyl), SO 2 (C 3-7 branched alkyl), —SO 2 (C 3-7 cycloalkyl), COR 5 , CO 2 R 6 , CONR 7a R 7b , SO 2 NR 7a R 7b , NR 8a R 8b , NR 8a COR 9 , NR 8a SO 2 R 10 , and NR 8a SO 2 NR 11a R 11b .

3. A composition comprising an effective amount of at least one compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

4. The composition according to claim 3 , further comprising at least one excipient.

5. A method of treating a disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity, said method comprising administering to a subject an effective amount of at least one compound according to claim 1 , or a pharmaceutically acceptable salt thereof, to treat the disease.

6. The method of claim 5 , wherein the at least one compound is administered in a composition further comprising at least one excipient.

7. The method of claim 5 , wherein the disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity is: inflammatory bowel disease, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, or bipolar disorder.

8. The method of claim 6 , wherein the disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity is: inflammatory bowel disease, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, or bipolar disorder.

9. The compound of claim 1 , wherein each of R 1a and R 1b is C 1-6 linear alkyl.

10. The compound of claim 9 , wherein R 1a and R 1b are both methyl or both ethyl.

11. The compound of claim 1 , wherein the compound has a structure according to Formula (IX),

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , wherein R 2 is phenyl, 4-OH-phenyl, 3-OH-phenyl, 2-OH-phenyl, 4-CH 3 -phenyl, 3-CH 3 -phenyl, 2-CH 3 -phenyl, 4-OCH 3 -phenyl, 3-OCH 3 -phenyl, 2-OCH 3 -phenyl, 4-CN-phenyl, 3-CN-phenyl, 2-CN-phenyl, 4-F-phenyl, 3-F-phenyl, 2-F-phenyl, 4-Cl-phenyl, 3-Cl-phenyl, 2-Cl-phenyl, 4-Br-phenyl, 4-OCF 3 -phenyl, 3-OCF 3 -phenyl, 2-OCF 3 -phenyl, 4-isopropyl-phenyl, 3-isopropyl-phenyl, 2-isopropyl-phenyl, 4-cyclopropyl-phenyl, 3-cyclopropyl-phenyl, 2-cyclopropyl-phenyl, 4-morpholino-phenyl, 3-morpholino-phenyl, or 2-morpholino-phenyl.

13. The compound of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignees

• Univ Temple

Inventors

• Blass Benjamin E
• Canney Daniel J
• Blattner Kevin M

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title